These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32415310)

  • 1. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19).
    Cure E; Kucuk A; Cumhur Cure M
    Rheumatol Int; 2020 Jul; 40(7):1177-1179. PubMed ID: 32415310
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 may affect the endocrine pancreas by activating Na
    Cure E; Cumhur Cure M
    J Endocrinol Invest; 2020 Aug; 43(8):1167-1168. PubMed ID: 32468512
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytokine Storm in COVID19: A Neural Hypothesis.
    Ur A; Verma K
    ACS Chem Neurosci; 2020 Jul; 11(13):1868-1870. PubMed ID: 32605374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 and rheumatology: is shielding really necessary?
    Amani L; Warraich R; Patel N; Tahir H
    Br J Hosp Med (Lond); 2020 Jun; 81(6):1-3. PubMed ID: 32589537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Working Hypothesis for Glucose Metabolism and SARS-CoV-2 Replication: Interplay Between the Hexosamine Pathway and Interferon RF5 Triggering Hyperinflammation. Role of BCG Vaccine?
    Laviada-Molina HA; Leal-Berumen I; Rodriguez-Ayala E; Bastarrachea RA
    Front Endocrinol (Lausanne); 2020; 11():514. PubMed ID: 32733388
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
    Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
    Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 - A Kidney Perspective.
    Tang J
    R I Med J (2013); 2020 Sep; 103(8):19. PubMed ID: 32900006
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
    Schett G; Sticherling M; Neurath MF
    Nat Rev Immunol; 2020 May; 20(5):271-272. PubMed ID: 32296135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?
    Willicombe M; Thomas D; McAdoo S
    J Am Soc Nephrol; 2020 Jun; 31(6):1145-1146. PubMed ID: 32312797
    [No Abstract]   [Full Text] [Related]  

  • 10. Is a "Cytokine Storm" Relevant to COVID-19?
    Sinha P; Matthay MA; Calfee CS
    JAMA Intern Med; 2020 Sep; 180(9):1152-1154. PubMed ID: 32602883
    [No Abstract]   [Full Text] [Related]  

  • 11. [The endocrine and metabolic link between COVID-19, diabetes and obesity].
    Weis N; Thorsteinsson K; Martinussen C; Madsbad S
    Ugeskr Laeger; 2020 Jul; 182(29):. PubMed ID: 32734864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 cytokine storm: the interplay between inflammation and coagulation.
    Jose RJ; Manuel A
    Lancet Respir Med; 2020 Jun; 8(6):e46-e47. PubMed ID: 32353251
    [No Abstract]   [Full Text] [Related]  

  • 13. The Management of Cytokine Storm in COVID-19.
    Rumende CM; Susanto EC; Sitorus TP
    Acta Med Indones; 2020 Jul; 52(3):306-313. PubMed ID: 33020343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulants and immunosuppressants in COVID-19: Bullets to Defeat MicroCLOTS.
    Turi S; Nardelli P; Landoni G
    Ann Card Anaesth; 2020; 23(3):258-259. PubMed ID: 32687078
    [No Abstract]   [Full Text] [Related]  

  • 15. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
    Carandini T; Pietroboni AM; Sacchi L; De Riz MA; Pozzato M; Arighi A; Fumagalli GG; Martinelli Boneschi F; Galimberti D; Scarpini E
    Mult Scler; 2020 Sep; 26(10):1268-1269. PubMed ID: 32463329
    [No Abstract]   [Full Text] [Related]  

  • 16. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.
    Takami A
    Int J Hematol; 2020 Jul; 112(1):122-124. PubMed ID: 32399895
    [No Abstract]   [Full Text] [Related]  

  • 17. The allergist/immunologist, the Janus gatekeeper of inflammation, COVID-19 and beyond.
    Bellanti JA; Settipane RA
    Allergy Asthma Proc; 2020 Nov; 41(6):395-396. PubMed ID: 33109305
    [No Abstract]   [Full Text] [Related]  

  • 18. COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence.
    Venerito V; Lopalco G; Iannone F
    Rheumatol Int; 2020 May; 40(5):827-828. PubMed ID: 32232551
    [No Abstract]   [Full Text] [Related]  

  • 19. Lymphopenia in COVID-19: Therapeutic opportunities.
    Fathi N; Rezaei N
    Cell Biol Int; 2020 Sep; 44(9):1792-1797. PubMed ID: 32458561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: more than a cytokine storm.
    Riva G; Nasillo V; Tagliafico E; Trenti T; Comoli P; Luppi M
    Crit Care; 2020 Sep; 24(1):549. PubMed ID: 32887652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.